App-Quantinova.ai

TEN-YEAR FOLLOW-UP OF 415 CLL PATIENTS TREATED WITH FLUDARABINE CYCLOPHOSPHAMIDE-BASED CHEMOIMMUNOTHERAPY IN THE FRONTLINE ARCTIC AND ADMIRE TRIALS, A COMPREHENSIVE ASSESSMENT OF PROGNOSTIC FACTORS

David Allsup - European Hematology Association (EHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

N/A

Cyclophosphamide

SUSTAINED IMPROVEMENTS IN PATIENT-REPORTED OUTCOMES WITH SUTIMLIMAB IN PATIENTS WITH COLD AGGLUTININ DISEASE: 1-YEAR FOLLOW-UP INTERIM RESULTS FROM THE CARDINAL STUDY

Alexander Rth - European Hematology Association (EHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Chronic obstructive pulmonary disease

N/A

VALIDATION AND CLINICAL APPLICATION OF AN UNSUPERVISED ANALYSIS APPROACH TO MEASURABLE RESIDUAL DISEASE TESTING IN ACUTE MYELOID LEUKEMIA

Nicholas McCarthy - European Hematology Association (EHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute myelocytic leukemia

N/A

BET INHIBITOR PELABRESIB DECREASES INFLAMMATORY CYTOKINES, IMPROVES BONE MARROW FIBROSIS AND FUNCTION, AND DEMONSTRATES CLINICAL RESPONSE IRRESPECTIVE OF MUTATION STATUS IN MYELOFIBROSIS PATIENTS

Patricia Keller - European Hematology Association (EHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Myelofibrosis

Ruxolitinib phosphate

A SURVEY OF HEALTHCARE PROFESSIONALS IN THE UNITED KINGDOM TO DESCRIBE CURRENT PATHWAYS AND MANAGEMENT PRACTICES IN CHRONIC MYELOID LEUKAEMIA: THE ADAPT CML SURVEY

Mhairi Copland - European Hematology Association (EHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Chronic Myelogenous Leukemia

N/A

SUTIMLIMAB, A TARGETED COMPLEMENT C1S INHIBITOR, IMPROVES QUALITY OF LIFE (QOL) IN PATIENTS WITH COLD AGGLUTININ DISEASE (CAD): RESULTS FROM THE RANDOMIZED, PLACEBO-CONTROLLED PHASE 3 CADENZA STUDY

Alexander Rth - European Hematology Association (EHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Chronic obstructive pulmonary disease

Mofezolac

GENETIC MARKERS AND OUTCOME IN FRONT LINE OBINUTUZUMAB PLUS CHLORAMBUCIL OR VENETOCLAX - UPDATED ANALYSIS OF THE CLL14 TRIAL

Eugen Tausch - European Hematology Association (EHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

N/A

Obinutuzumab

EARLY-ONSET OSTEOPENIA AND OSTEOPOROSIS IN PATIENTS WITH PYRUVATE KINASE DEFICIENCY

Hanny Al-Samkari - European Hematology Association (EHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Pyruvate kinase (PK) deficiency

AG348

COMPLICATIONS OF SICKLE CELL DISEASE IN EAST LONDON NEWBORN COHORT PATIENTS OVER THE YEARS 2015-2018

Muriel Soriano - European Hematology Association (EHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Sickle cell anemia

Hydroxyurea

SWATH-MS PROTEOMICS AS A NEW TOOL FOR DISCOVERING POTENTIAL DRUG TARGETS AND BIOMARKERS IN CHRONIC LYMPHOCYTIC LEUKEMIA

Umair T Khan - European Hematology Association (EHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Chronic Lymphocytic Leukemia

Trypsin

COVID-19 MORTALITY IN CONCURRENT MULTIPLE MYELOMA (MM) – A PROSPECTIVE AND COMPARATIVE CASE SERIES THROUGH THE FIRST AND SECOND WAVE OF THE SARS-COV-2 PANDEMIC IN A UK TERTIARY HAEMATOLOGY CENTRE

Sammy Shaya - European Hematology Association (EHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Multiple Myeloma

N/A

BENEFIT OF CONTINUING THERAPY WITH LUSPATERCEPT IN PATIENTS WITH BETA-THALASSEMIA WHO DO NOT ACHIEVE ≥33% REDUCTION IN RED BLOOD CELL (RBC) TRANSFUSION BURDEN (TB) IN WEEKS 13–24 IN THE BELIEVE TRIAL

Antonio Piga - European Hematology Association (EHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Beta-thalassemia

luspatercept

CYTOPENIA MANAGEMENT IN THE PHASE 3 VIALE-C STUDY OF VENETOCLAX PLUS LOW-DOSE CYTARABINE FOR PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA INELIGIBLE FOR INTENSIVE CHEMOTHERAPY

Andrew H. Wei - European Hematology Association (EHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute myelocytic leukemia

Cytarabine liposomal

ADORE: A RANDOMIZED, OPEN-LABEL, PHASE 1/2 OPEN-PLATFORM STUDY EVALUATING SAFETY AND EFFICACY OF NOVEL RUXOLITINIB COMBINATIONS IN PATIENTS WITH MYELOFIBROSIS

David Ross - European Hematology Association (EHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Myelofibrosis

SelG1

RETROSPECTIVE STUDY ON MANTLE CELL LYMPHOMA (MCL) AND TREATMENT OUT-COME- A SINGLE CENTER EXPERIENCE.

Ezzat Elhassadi - European Hematology Association (EHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Mantle cell lymphoma

TP53

LONG-TERM ANALYSES FROM L-MIND, A PHASE II STUDY OF TAFASITAMAB (MOR208) COMBINED WITH LENALIDOMIDE IN PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (R/R DLBCL)

Johannes Dll - European Hematology Association (EHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Diffuse large B-cell lymphoma

Lenalidomide

EFFICACY AND SAFETY OF AVAPRITINIB IN PATIENTS WITH ADVANCED SYSTEMIC MASTOCYTOSIS: INTERIM RESULTS FROM THE OPEN-LABEL, SINGLE-ARM, PHASE 2 PATHFINDER STUDY

Andreas Reiter - European Hematology Association (EHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Myeloid neoplasms

Midostaurin

DISEASE RISK IN TP53 MUTANT ACUTE MYELOID LEUKAEMIA FOLLOWING AN ALLOGENEIC STEM CELL TRANSPLANT IS DEPENDENT ON THE PRESENCE OF CO-EXISTING CYTOGENETIC FEATURES: A REPORT FROM THE ALWP OF THE EBMT

Justin Loke - European Hematology Association (EHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute myelocytic leukemia

TP53

OVERALL AND PROGRESSION-FREE SURVIVAL IN PATIENTS TREATED WITH FEDRATINIB AS FIRST-LINE MYELOFIBROSIS (MF) THERAPY AND AFTER PRIOR RUXOLITINIB (RUX): RESULTS FROM THE JAKARTA AND JAKARTA2 TRIALS

Claire Harrison - European Hematology Association (EHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Myelofibrosis

Ruxolitinib phosphate

A PHASE IB/II STUDY OF IVOSIDENIB WITH VENETOCLAX +/- AZACITIDINE IN IDH1-MUTATED MYELOID MALIGNANCIES

Curtis Lachowiez - European Hematology Association (EHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute myelocytic leukemia

Vidaza

Filters

45280 Abstracts